Skip to main content

Table 1 KRAS mutations

From: Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

KRASmutant

Exon

Codon

Hot spot site

Amino acid

No. of patients

%

2

12

  

24

40.6

  

c.34 G > A

p.Gly12Ser

1

1.6

  

c.35 G > A

p.Gly12Asp

15

25.4

  

c.35 G > T

p.Gly12Val

7

11.8

  

c.35 G > C

p.Gly12Ala

1

1.6

 

13

  

4

6.7

  

c.37_39 dupl

p.Gly13dupl

1

1.6

  

c.37

-

-

-

  

c.38 G > A

p.Gly13Asp

3

5

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us